Is Nederland klaar voor gepersonaliseerde borstkankerscreening?

One-size-fits-all breast cancer screening no longer reflects the current state of knowledge and technology. 8% of the participants in the Dutch Breastcancer Screening Program have extremely dense breasts, which is coupled to a strongly increased risk of breast cancer. In addition, for this group of approximately 80,000 women per year, mammography is only 60% sensitive. The DENSE trial showed that supplemental MRI after a negative mammogram reduced the number of interval cancers by more than 80%. The Dutch Health Council however subsequently recommended to consider contrast-enhanced mammography (CEM) as a screening tool. At the request of the Ministry of Health-Welfare and Sport, simultaneous research is being set up to study both CEM and the introduction of CEM and "accelerated" (abbreviated) MRI. This article explains the differences between the two techniques and discusses the role both could play in screening this large group of women when politicians give green light.

Conflict of interest and financial support: potential conflicts of interest have been reported for this article. ICMJE forms provided by the authors are available online along with the full text of this article.